Measles virus neutralizing antibody response, cell-mediated immunity, and immunoglobulin G antibody avidity before and after receipt of a third dose of measles, mumps, and rubella vaccine in young adults

Journal of Infectious Diseases

Volumn 213, Issue 7, 2016, Pages 1115-1123

  Fiebelkorn, Amy Parker ^a   Coleman, Laura A ^b,e   Belongia, Edward A ^b   Freeman, Sandra K ^b   York, Daphne ^b   Bi, Daoling ^a   Kulkarni, Ashwin ^c   Audet, Susette ^c   Mercader, Sara ^a   McGrew, Marcia ^a   Hickman, Carole J ^a   Bellini, William J ^a   Shivakoti, Rupak ^d,f   Griffin, Diane E ^d   Beeler, Judith ^c  

^a NATIONAL CENTER FOR IMMUNIZATION AND RESPIRATORY DISEASES   (United States)

^b MARSHFIELD CLINIC   (United States)

^c CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^d JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^e Johns Hopkins School of Medicine ^*  (United States)

^f JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Cell mediated immunity; Immunization; Measles; Measles vaccine immunogenicity; Measles virus antibody avidity; Mumps; Rubella (MMR) vaccine; Third dose of measles; Vaccinepreventable disease

Indexed keywords

IMMUNOGLOBULIN G ANTIBODY; MEASLES MUMPS RUBELLA VACCINE; NEUTRALIZING ANTIBODY; IMMUNOGLOBULIN G; VIRUS ANTIBODY;

ADULT; ANTIBODY BLOOD LEVEL; ANTIBODY RESPONSE; ARTICLE; CELLULAR IMMUNITY; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; IMMUNOGENICITY; MALE; NORMAL HUMAN; PRIORITY JOURNAL; T LYMPHOCYTE; YOUNG ADULT; ADOLESCENT; ANTIBODY AFFINITY; BLOOD; COHORT ANALYSIS; IMMUNIZATION; IMMUNOLOGY; LONGITUDINAL STUDY; MEASLES VIRUS; ODDS RATIO; PHYSIOLOGY; SERODIAGNOSIS;

ADOLESCENT; ADULT; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; ANTIBODY AFFINITY; COHORT STUDIES; FEMALE; HUMANS; IMMUNITY, CELLULAR; IMMUNIZATION SCHEDULE; IMMUNOGLOBULIN G; LONGITUDINAL STUDIES; MALE; MEASLES VIRUS; MEASLES-MUMPS-RUBELLA VACCINE; NEUTRALIZATION TESTS; ODDS RATIO; YOUNG ADULT;

EID: 84962546191     PISSN: 00221899     EISSN: 15376613     Source Type: Journal    
DOI: 10.1093/infdis/jiv555     Document Type: Article

References (31)

1. Strebel PM, Papania MJ, Parker Fiebelkorn A, Halsey NA. Measles vaccine. In: Plotkin SA, Orenstein WA, Offit P. Vaccines. 6th ed. Elsevier Saunders, 2013:352-87.
2. Katz SL, Hinman AR. Summary and conclusions: measles elimination meeting, 16-17 March 2000. J Infect Dis 2004; 189(suppl 1):S43-7.
3. Markowitz LE, Preblud SR, Fine PE, Orenstein WA. Duration of live measles vaccine- induced immunity. Pediatr Infect Dis J 1990; 9:101-10.
4. Ogbuanu IU, Kutty PK, Hudson JM, et al. Impact of a third dose of measlesmumps- rubella vaccine on a mumps outbreak. Pediatrics 2012; 130:e1567-74.
5. Nelson GE, Aguon A, Valencia E, et al. Epidemiology of a mumps outbreak in a highly vaccinated island population and use of a third dose of measles-mumpsrubella vaccine for outbreak control- Guam 2009-2010. Pediatr Infect Dis J 2013; 32:374-80.
6. Advisory Committee on Immunization Practices, Centers for Disease Control and Prevention. Immunization of health-care personnel: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2011; 60(RR-7):1-45.
7. Military Vaccine Agency. Mumps infection and mumps vaccine: information paper. http://www.vaccines.mil/documents/1485MIP-Mumps.pdf. Accessed August 29.
8. McLean HQ, Fiebelkorn AP, Temte JL, Wallace GS. Prevention of measles, rubella, congenital rubella syndrome, and mumps, 2013: summary recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2013; 62(RR-04):1-34.
9. LeBaron CW, Bi D, Sullivan BJ, Beck C, Gargiullo P. Evaluation of potentially common adverse events associated with the first and second doses of measlesmumps- rubella vaccine. Pediatrics 2006; 118:1422-30.
10. LeBaron CW, Beeler J, Sullivan BJ, et al. Persistence of measles antibodies after 2 doses of measles vaccine in a postelimination environment. Arch Pediatr Adolesc Med 2007; 161:294-301.
11. LeBaron CW, Forghani B, Beck C, et al. Persistence of mumps antibodies after 2 doses of measles-mumps-rubella vaccine. J Infect Dis 2009; 199:552-60.
12. LeBaron CW, Forghani B, Matter L, et al. Persistence of rubella antibodies after 2 doses of measles-mumps-rubella vaccine. J Infect Dis 2009; 200:888-99.
13. Fiebelkorn AP, Coleman LA, Belongia EA, et al. Mumps antibody response in young adults after a third dose of measles-mumps-rubella vaccine. Open Forum Infect Dis 2014; doi:10.1093/ofid/ofu094.
14. Albrecht P, Herrmann K, Burns GR. Role of virus strain in conventional and enhanced measles plaque neutralization test. J Virol Methods 1981; 3:251-60.
15. Lin WH, Vilalta A, Adams RJ, Rolland A, Sullivan SM, Griffin DE. Vaxfectin adjuvant improves antibody responses of juvenile rhesus macaques to a DNAvaccine encoding the measles virus hemagglutinin and fusion proteins. J Virol 2013; 87:6560-8.
16. Mercader S, Garcia P, Bellini WJ. Measles virus IgG avidity assay for use in classification of measles vaccine failure in measles elimination settings. Clin Vaccine Immunol 2012; 19:1810-7.
17. Chen RT, Markowitz LE, Albrecht P, et al. Measles antibody: reevaluation of protective titers. J Infect Dis 1990; 162:1036-42.
18. Samb B, Aaby P, Whittle HC, et al. Serologic status and measles attack rates among vaccinated and unvaccinated children in rural Senegal. Pediatr Infect Dis J 1995; 14:203-9.
19. Watson JC, Hadler SC, Dykewicz CA, Reef S, Phillips L. Measles, mumps, and rubella- vaccine use and strategies for elimination ofmeasles, rubella, and congenital rubella syndrome and control of mumps: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 1998; 47(RR-8):1-57.
20. Yeung LF, Lurie P, Dayan G, et al. A limited measles outbreak in a highly vaccinated US boarding school. Pediatrics 2005; 116:1287-91.
21. Vitek CR, Aduddell M, Brinton MJ, Hoffman RE, Redd SC. Increased protections during a measles outbreak of children previously vaccinated with a second dose of measles-mumps-rubella vaccine. Pediatr Infect Dis J 1999; 18:620-3.
22. Davidkin I, Jokinen S, Broman M, Leinikki P, Peltola H. Persistence of measles, mumps, and rubella antibodies in an MMR-vaccinated cohort: a 20-year followup. J Infect Dis 2008; 197:950-6.
23. Davidkin I, Valle M. Vaccine-induced measles virus antibodies after two doses of combined measles, mumps and rubella vaccine: a 12-year follow-up in two cohorts. Vaccine 1998; 16:2052-7.
24. Rosen JB, Rota JS, Hickman CJ, et al. Outbreak of measles among persons with prior evidence of immunity, New York City, 2011. Clin Infect Dis 2014; 58:1205-10.
25. Poland GA, Jacobson RM, Schaid D, Moore SB, Jacobsen SJ. The association between HLA class I alleles and measles vaccine-induced antibody response: evidence of a significant association. Vaccine 1998; 16:1869-71.
26. De Serres G, Boulianne N, Defay F, et al. Higher risk of measles when the first dose of a two-dose schedule is given at 12-14 versus 15 months of age. Clin Infect Dis 2012; 55:394-402.
27. Hickman CJ, Hyde TB, Sowers SB, et al. Laboratory characterization of measles virus infection in previously vaccinated and unvaccinated individuals. J Infect Dis 2011; 204(suppl 1):S549-58.
28. Lin WH, Griffin DE, Rota PA, et al. Successful respiratory immunization with dry powder live-attenuated measles virus vaccine in rhesus macaques. Proc Natl Acad Sci U S A 2011; 108:2987-92.
29. Wong-Chew RM, Beeler JA, Audet S, Santos JI. Cellular and humoral immune responses to measles in immune adults re-immunized with measles vaccine. J Med Virol 2003; 70:276-80.
30. Haralambieva IH, Ovsyannikova IG, O'Byrne M, Pankratz VS, Jacobson RM, Poland GA. A large observational study to concurrently assess persistence of measles specific B-cell and T-cell immunity in individuals following two doses of MMR vaccine. Vaccine 2011; 29:4485-91.
31. Cohen BJ, Parry RP, Doblas D, et al. Measles immunity testing: comparison of two measles IgG ELISAs with plaque reduction neutralisation assay. J Virol Methods 2006; 131:209-12.